Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines AgencyBusiness Wire • 08/14/26
Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?Zacks Investment Research • 08/12/26
The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More24/7 Wall Street • 08/12/26
Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent ClockThe Motley Fool • 08/11/26
Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?The Motley Fool • 08/10/26
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's ZepboundThe Motley Fool • 08/07/26
Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost CutsZacks Investment Research • 08/05/26
Compared to Estimates, Pfizer (PFE) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/04/26
Pfizer Ducks Continued Covid Fallout As Hard-Fought Obesity Readout LoomsInvestors Business Daily • 08/04/26
Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid productsCNBC • 08/04/26